Armata Pharmaceuticals
ARMP
25 hedge funds and large institutions have $1.6M invested in Armata Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 3 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
25% more funds holding
Funds holding: 20 → 25 (+5)
0.19% less ownership
Funds ownership: 3.76% → 3.57% (-0.19%)
72% less capital invested
Capital invested by funds: $5.73M → $1.6M (-$4.13M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$208K |
| 2 |
HF
HRT Financial
New York
|
+$110K |
| 3 |
E
Ergoteles
New York
|
+$72.8K |
| 4 |
Jane Street
New York
|
+$52.1K |
| 5 |
Millennium Management
New York
|
+$40.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$634K |
| 2 |
SF
Synovus Financial
Columbus,
Georgia
|
-$202K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$23K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$169 |
ARMP Hedge Fund Activity: Q4 2022 in Review
25 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q4 2022, worth a combined $1.6M — down 72% from $5.73M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ARMP positions and 3 closed out — a net gain of 6 holders — while 9 added to existing stakes and 2 trimmed.
The largest buyer was Bridgeway Capital Management, adding an estimated $208K. The largest seller was Vanguard Group, cutting an estimated $634K.
- 25 institutional investors held Armata Pharmaceuticals (ARMP) as of Q4 2022, up from 20 in Q3 2022.
- Funds reported $1.6M of Armata Pharmaceuticals stock for Q4 2022, down 72% quarter-over-quarter.
- 9 funds opened new Armata Pharmaceuticals positions in Q4 2022 and 3 closed out, a net change of +6 holders.
- The largest Armata Pharmaceuticals buyer in Q4 2022 was Bridgeway Capital Management, an estimated $208K added.
- The largest Armata Pharmaceuticals seller in Q4 2022 was Vanguard Group, an estimated $634K sold.
Based on aggregated 13F filings for Q4 2022.